SUPPLEMENTARY TABLE 1. Chain of indirect evidence by unknown
SUPPLEMENTARY TABLE 1. Chain of indirect evidence
How would universal screening for 
hepatitis C affect the number (and 
composition) of people who screen 
positive for HCV infection?
How many additional persons would be 
linked to care?
Do desirable treatment effects outweigh 
undesirable effects?
K.Q.1.a. What is the prevalence of HCV 
infection in the United States?
In the general population?
By risk groups?
K.Q.2.a. What is the diagnostic accuracy
of HCV antibody testing?*
K.Q.2.b. What are harms of hepatitis C 
screening?†
K.Q.2.c. What proportion of people who 
screen positive for HCV infection are 
linked to care?§¶
K.Q.3.a. What is the effect of DAA 
treatment on HCV viral load?*
K.Q.3.b. What is the effect of DAA 
treatment on morbidity (including 
cirrhosis and hepatocellular carcinoma)?
*
K.Q.3.c. What is the effect of DAA 
treatment on mortality (HCVspecific and
allcause)?*
K.Q.3.d. What are the adverse effects of 
DAA treatment?*
Abbreviations: HCV = hepatitis C virus; DAA = direct acting antiviral.
* Previously welldescribed and therefore not included in this review.
† U.S. and nonU.S. studies included.
§ U.S. studies only included.
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¶ For all adult review only.SUPPLEMENTARY TABLE 2. Search strategy for all adult literature review
Search Query: Does universal screening for hepatitis C virus infection among adults aged 18 years and older, compared to riskbased 
screening, reduce morbidity and mortality?
Database Strategy Run Date Records
Medline (OVID)
1946–
(exp Hepatitis C/ AND *Mass Screening/) 
OR ((Hepatitis C ADJ5 screen*) OR (hepC 
ADJ5 screen*) OR (HCV ADJ5 screen*) 
OR (Hepatitis C ADJ5 test*) OR (hepC 
ADJ5 test*) OR (HCV ADJ5 test*)).ti,ab. 
OR (*hepatitis C/ AND (screen* OR 
test*).ti)
Limit 2010– ; English
8/6/2018 3310
Embase (OVID)
1996–
(exp Hepatitis C/ AND *Mass Screening/) 
OR ((Hepatitis C ADJ5 screen*) OR (hepC 
ADJ5 screen*) OR (HCV ADJ5 screen*) 
OR (Hepatitis C ADJ5 test*) OR (hepC 
ADJ5 test*) OR (HCV ADJ5 test*)).ti,ab. 
OR (*hepatitis C/ AND (screen* OR 
test*).ti)
Limit 2010– ; English; Exclude Medline 
Journals
8/6/2018 559 - 161 duplicates = 398 unique 
items
CINAHL (EBSCO) ((MH “Hepatitis C”+) AND (MM “Mass 
Screening”)) OR ((“Hepatitis C” N5 
screen*) OR (hepC N5 screen*) OR (HCV 
N5 screen*) OR (“Hepatitis C” N5 test*) 
OR (hepC N5 test*) OR (HCV N5 test*)) 
OR ((MM “hepatitis C”) AND (TI (screen* 
OR test*)))
Limit 2010– ; exclude Medline records ; 
English
8/6/2018 210 - 128 duplicates = 82 unique 
items
Scopus TITLE-ABS-KEY((“Hepatitis C” W/5 
screen*) OR (hepC W/5 screen*) OR (HCV
8/6/2018 1769 - 846 duplicates = 923 unique 
items
2
W/5 screen*) OR (“Hepatitis C” W/5 test*) 
OR (hepC W/5 test*) OR (HCV W/5 test*))
AND NOT INDEX(medline)
Limit 2010– ; English
Cochrane Library ((“Hepatitis C” NEAR/5 screen*) OR 
(hepC NEAR/5 screen*) OR (HCV 
NEAR/5 screen*) OR (“Hepatitis C” 
NEAR/5 test*) OR (hepC NEAR/5 test*) 
OR (HCV NEAR/5 test*)):ti,ab
Limit 2010– ; English
8/6/2018 250 - 96 duplicates = 154 unique 
items
3
SUPPLEMENTARY TABLE 3. Search strategy for pregnant women literature review
Search Query: Does universal screening for hepatitis C virus infection among pregnant women, compared to riskbased screening, reduce 
morbidity and mortality among mothers and their children?
Database Strategy Run Date Records
Medline (OVID)
1946–
Hepatitis C OR hepC OR HCV
AND
Pregnanc* OR pregnant OR maternal
AND
Screen* OR test*
Limit 1998– ;
7/2/2018 592
Embase (OVID)
1947–
Hepatitis C OR hepC OR HCV
AND
Pregnanc* OR pregnant OR maternal
AND
Screen* OR test*
Limit 1998– ;
7/2/2018 1226 - 464 duplicates = 762 unique 
items
CINAHL (EBSCO) “Hepatitis C” OR hepC OR HCV
AND
Pregnanc* OR pregnant OR maternal
AND
Screen* OR test*
Limit 1998– ; exclude Medline records
7/2/2018 38 - 19 duplicates = 19 unique items
Scopus TITLE-ABS-KEY((“Hepatitis C” OR hepC
OR HCV) AND (Pregnanc* OR pregnant 
OR maternal) AND (Screen* OR test*)) 
AND NOT INDEX(medline)
7/2/2018 333 - 216 duplicates = 117 unique 
items
Cochrane Library ((“Hepatitis C” OR hepC OR HCV) AND 
(Pregnanc* OR pregnant OR maternal) 
AND (Screen* OR test*)):ti,ab
7/2/2018 23 - 13 duplicates = 10 unique items
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SUPPLEMENTARY TABLE 4. Search strategy for supplementary all adult literature review
Search Query: Does universal screening for hepatitis C virus infection among adults aged 18 years and older, compared to riskbased 
screening, reduce morbidity and mortality?
Database Strategy Records for run date 8/6/2018 Records for run date 11/15/2019
Medline (OVID)
1946–
(exp Hepatitis C/ AND 
*Mass Screening/) OR 
((Hepatitis C ADJ5 
screen*) OR (hepC ADJ5 
screen*) OR (HCV ADJ5 
screen*) OR (Hepatitis C 
ADJ5 test*) OR (hepC 
ADJ5 test*) OR (HCV 
ADJ5 test*)).ti,ab. OR 
(*hepatitis C/ AND 
(screen* OR test*).ti)
Limit 2010– ; English
Update: (201808* OR 
201809* OR 201810* OR
201811* OR 201812* OR
2019*).dt
3310 682
Embase (OVID)
1996–
(exp Hepatitis C/ AND 
*Mass Screening/) OR 
((Hepatitis C ADJ5 
screen*) OR (hepC ADJ5 
screen*) OR (HCV ADJ5 
screen*) OR (Hepatitis C 
ADJ5 test*) OR (hepC 
ADJ5 test*) OR (HCV 
ADJ5 test*)).ti,ab. OR 
(*hepatitis C/ AND 
(screen* OR test*).ti)
Limit 2010– ; English; 
559 - 561 duplicates = 398 unique 
items
247 - 51 duplicates = 196 unique 
items
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Exclude Medline Journals
Update: (201808* OR 
201809* OR 201810* OR
201811* OR 201812* OR
2019*).dc
CINAHL (EBSCO) ((MH “Hepatitis C”+) 
AND (MM “Mass 
Screening”)) OR 
((“Hepatitis C” N5 
screen*) OR (hepC N5 
screen*) OR (HCV N5 
screen*) OR (“Hepatitis 
C” N5 test*) OR (hepC 
N5 test*) OR (HCV N5 
test*)) OR ((MM 
“hepatitis C”) AND (TI 
(screen* OR test*)))
Limit 2010– ; exclude 
Medline records ; English
Update: August 2018–
current
210 - 128 duplicates = 82 unique 
items
105 - 59 duplicates = 46 unique 
items
Scopus TITLE-ABS-
KEY((“Hepatitis C” W/5 
screen*) OR (hepC W/5 
screen*) OR (HCV W/5 
screen*) OR (“Hepatitis 
C” W/5 test*) OR (hepC 
W/5 test*) OR (HCV W/5
test*)) AND NOT 
INDEX(medline)
Limit 2010– ; English
1769 - 846 duplicates = 923 unique 
items
193 - 129 duplicates = 64 unique 
items
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Update: August 2018–
current
Cochrane Library ((“Hepatitis C” NEAR/5 
screen*) OR (hepC 
NEAR/5 screen*) OR 
(HCV NEAR/5 screen*) 
OR (“Hepatitis C” 
NEAR/5 test*) OR (hepC 
NEAR/5 test*) OR (HCV 
NEAR/5 test*)):ti,ab 
Limit 2010– ; English
Update: August 2018–
current
250 - 96 duplicates = 154 unique 
items
61 - 11 duplicates = 50 unique 
items
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SUPPLEMENTARY TABLE 5. Search strategy for supplementary pregnant women literature review
Search Query: Does universal screening for hepatitis C virus infection among pregnant women, compared to riskbased screening, reduce 
morbidity and mortality among mothers and their children?
Database Strategy Records for run date 7/2/2018 Records for run date 10/29/2019
Medline (OVID)
1946–
Hepatitis C OR hepC OR 
HCV
AND
Pregnanc* OR pregnant 
OR maternal
AND
Screen* OR test*
Limit 1998– ; (201807* 
OR 201808* OR 201809*
OR 201810* OR 201811*
OR 201812* OR 
2019*).dt
592 69
Embase (OVID)
1947–
Hepatitis C OR hepC OR 
HCV
AND
Pregnanc* OR pregnant 
OR maternal
AND
Screen* OR test*
Limit 1998– ; (201807* 
OR 201808* OR 201809*
OR 201810* OR 201811*
OR 201812* OR 
2019*).dc
1226 - 466 duplicates = 762 unique 
items
155 - 47 duplicates = 108 unique 
items
CINAHL (EBSCO) “Hepatitis C” OR hepC 
OR HCV
AND
Pregnanc* OR pregnant 
OR maternal
38 - 19 duplicates = 19 unique items 12 - 8 duplicates = 4 unique items
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AND
Screen* OR test*
Limit 1998– ; exclude 
Medline records
Scopus TITLE-ABS-KEY 
((“Hepatitis C” OR hepC 
OR HCV) AND 
(Pregnanc* OR pregnant 
OR maternal) AND 
(Screen* OR test*)) AND
NOT INDEX (medline)
333 - 216 duplicates = 117 unique 
items
21 - 17 duplicates = 4 unique items
Cochrane Library ((“Hepatitis C” OR hepC 
OR HCV) AND 
(Pregnanc* OR pregnant 
OR maternal) AND 
(Screen* OR test*)):ti,ab
23 - 13 duplicates = 10 unique items 12 - 2 duplicates = 10 unique items
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SUPPLEMENTARY TABLE 6. Hepatitis C prevalence and linkagetocare, general population
Author, 
publicatio
n year
Years of 
study;
design
Descriptio
n Setting
Anti-
HCV 
tested
Anti-
HCV 
positivity
RNA 
positivity
Follow-up
appt. 
arranged
Attended 
follow-up 
appt. Treated
Achieved 
SVR
Abara (1), 
2019
2010–2017; 
Retrospective
Screening 
among 
deceased 
organ donors
Organ 
Procurement and
Transplantation 
Network
3,725/70,41
4 (5.3%)
1,306/2,378
* (54.9%)
Dodd (2), 
2016
2011–2012; 
Surveillance
Routine 
testing of 
donated 
blood supply
American Red 
Cross; Blood 
Systems, Inc.; 
and New York 
Blood Center 
supply
All 
samples 
tested
2,968/14,78
6,584 
(0.02%)†
Dong (3), 
2017
2016; Pilot Pharmacists 
training to 
provide HCV
point-of-care 
rapid testing
Community 
pharmacy, 
Mission 
Wellness 
Pharmacy, San 
Francisco, 
California
1/83 (1.2%)
Hofmeister 
(4, 5), 2018§
2013–2016; 
Epidemiologic 
study
NHANES data 
and data for 
populations not 
represented in 
NHANES
4,101,200/2
44,869,800 
(1.7%)
2,266,700/4,
088,173 
(55.5%)¶
Kim (6), 
2019
2016–2018; 
Retrospective
Examining 
screening 
rates
Women of 
reproductive age 
at safety net 
hospital in San 
Francisco
7,406/19,
121 
(38.7%)
206/7,406 
(2.8%)
105/168 
(62.5%)
41 34/41 
(82.9%)
Klevens (7), 
2016**
2010–2013; 
Cross-sectional
Laboratory 
data analysis
Quest 
Diagnostics 
laboratory data
352,646/5,6
51,742 
(6.2%)
292,681/352
,646 
(83.0%)
Kugelmas 
(8), 2017
2015–2016; 
Prospective
Direct store 
advertising
45 Walgreen 
pharmacies in 9 
major 
metropolitan 
areas
103/1,296 
(7.9%)
Saab (9), 
2019
2018; 
Retrospective
Results of 
hospital 
University of 
California, Los 
238/17,512 
(1.4%)
70/190 
(36.8%)
53/70 
(75.7%)
10
screenings for
HCV
Angeles Health 
Care System
Viner (10), 
2015††
2010–2013; 
Epidemiologic
Surveillance data
from 
Philadelphia 
Department of 
Public Health 
13,596/1,58
4,848 
(0.9%)
6,383/13,59
6 (47.0%)§§
Abbreviations: anti-HCV = hepatitis C virus antibody; HCV = hepatitis C virus; RNA = ribonucleic acid; SVR = sustained virologic response; 
NHANES = National Health and Nutrition Examination Survey.
* Number testing anti-HCV positive during time period.
† RNA positive.
§ Includes incarcerated.
¶ From Rosenberg et al. (5).
** Both anti-HCV and RNA testing.
†† Population estimates used 2010 census data for Philadelphia County, estimated 47,207 with HCV.
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§§ Among those with anti-HCV positivity.SUPPLEMENTARY TABLE 7. Hepatitis C prevalence and linkagetocare, emergency departments
Author, 
publicatio
n year
Years of 
study;
design
Descriptio
n Setting
Anti-
HCV 
tested
Anti-
HCV 
positivity
RNA 
positivity
Follow-up
appt. 
arranged
Attended 
follow-up 
appt. Treated
Achieved 
SVR
Allison (11), 
2016
2014–2015; 
Cross-sectional
Interview and
screening
Birth cohort 
patients 
presenting to 
large public 
urban ED, 
Bellevue 
Hospital Center, 
New York City
383/915 
(41.9%)
28/383 
(7.3%)
19/21 
(90.5%)
21/19 
(>100.0%)
4/19 
(21.1%)
1/4 (25.0%)
Anderson 
(12), 2017*
2014–2015; 
Multicenter 
retrospective 
cohort
Triage-based 
screening 
strategy
Birth cohort and 
IDU patients 
presenting to 2 
urban EDs: 
public ED, 
Highland 
Hospital, 
Oakland, 
California and 
academic ED, 
University of 
Alabama at 
Birmingham
/55,335 532 301/435 
(69.2%)
158/301 
(52.5%)
97/158 
(61.4%)
24/97 
(24.7%)
19/24 
(79.2%)
Anderson 
(13), 2016
2015; 
Prospective 
observational 
pilot
Screening 
initiative, 
provider 
training
IDU patients 
presenting to 
publicly-funded 
urban ED, 
Alameda Health 
System, 
Highland 
Hospital, 
Oakland, 
California
155/14,2
53 
(1.1%)
40/155 
(25.8%)
22/32 
(68.8%)
19/22 
(86.4%)
3/19 
(15.8%)
1/3 (33.3%)
Cowan (14), 
2018
2012–2013; 
Randomized 
controlled trial
Bundled 
HIV/HCV 
screening
Inner city 
medical center, 
Jacobi Medical 
Center, Bronx, 
New York
187/234 
(79.9%)
1/187 
(0.5%)
Donnelly 
(15), 2016†
2013–2015; 
Geospatial 
Opt-out 
screening
Urban 
emergency 
1,014/8,742 
(11.6%)
12
analysis department, 
University of 
Alabama, 
Birmingham, 
Alabama
Franco (16), 
2016
2013–2014; 
Retrospective 
cohort
Opt-out 
screening, 
LTC 
coordinator
Birth cohort 
patients at 
academic tertiary
care center, 
University of 
Alabama at 
Birmingham
473/4,371 
(10.8%)
332/402 
(82.6%)
148/332 
(44.6%)
117/148 
(79.1%)
Hoenig (17), 
2019
2017–2018; 
Pilot study
Opt-out 
screening 
program
Birth cohort 
patients at 2 
academic centers
in San Diego, 
California
90/905 
(9.9%)
31/61 
(50.8%)
13/31 
(41.9%)
Hsieh (18), 
2016
2013; 
Seroprevalence 
study
Excess blood 
tested for 
HCV
Urban 
emergency 
department, 
Johns Hopkins 
Hospital, 
Baltimore, 
Maryland
4,713/8,5
82 
(54.9%)
652/4,713 
(13.8%)
87/100 
(87.0%)
Hsieh (19), 
2018
2015–2016; 
Retrospective 
cohort
Opt-out 
screening
Johns Hopkins 299/5,03
9 (5.9%)
6/299 
(2.0%)
Kang (20), 
2018
2016; 
Retrospective 
cohort study
Opt-out 
screening
Birth cohort 
patients, large 
ED in New 
Jersey
2,928/14,
000 
(20.9%)
192/2,928 
(6.6%)
71/167 
(42.5%)
Merchant 
(21), 2015
2010–2012; 
Randomized 
controlled trial
Drug misusing 
patients at two 
urban EDs 
affiliated with 
medical school 
in New England, 
Miriam Hospital 
and Rhode Island
Hospital
5/346 
(1.4%)
Merchant 
(22), 2014
2011–2012; 
Randomized 
Patients 
reporting drug 
256/470 
(54.5%)
7/256 
(2.7%)
13
controlled trial use in 2 urban 
EDs, Miriam 
Hospital and 
Rhode Island 
Hospital
Privette (23), 
2018§
2016–2017; 
Prospective
Screening 
initiative
Participants were
Level A and 
Level B trauma 
activations, 
South Carolina
70/1,217 
(5.8%)
45¶/70 
(64.3%)
40/46 
(87.0%)
10/27 
(37.0%)
Schechter-
Perkins (24), 
2018
2016–2017; 
Retrospective
EMR prompt,
opt-out 
screening
Urban safety net 
hospital ED, 
Boston Medical 
Center, 
Massachusetts
3,808/19,
905 
(19.1%)
504/3,808 
(13.2%)
292/493 
(59.2%)
102/292 
(34.9%)
66/102 
(64.7%)
Simoncini 
(25), 2019
2016–2017 Prospective 
screening of 
trauma 
patients with 
consent
Level 1 trauma 
center. 
Philadelphia, 
Pennsylvania
1,160/1,4
70 
(78.9%)
162/1,160 
(14.0%)
67/97 
(69.1%)
46/67 
(68.7%)
55/162 
(34.0%)
Torian (26), 
2018
2015; Cross-
sectional 
blinded 
serosurvey
Excess blood 
tested for 
HCV
Large academic 
tertiary care 
hospital in 
poorest county 
urban county in 
United States, 
Bronx, New 
York
4,989/16,
340 
(30.5%)
372/4,989 
(7.5%)
167/314 
(53.2%)
Ullo (27), 
2019
2018; 
Retrospective
Screening 
initiative
Birth cohort 
patients with ED 
visits at urban 
tertiary care 
hospital in New 
Jersey
1,007/30
23 
(33.3%)
112/1,007 
(11.1%)
28/38 
(73.6%)
White (28), 
2016
2014–2015; 
Retrospective 
cohort
Timestamp 
analysis
Urban teaching 
hospital, 
Highland 
Hospital, 
Oakland, 
California
2,864/69,
639 
(4.1%)
272/2,864 
(9.5%)
14
White (29), 
2018
2016–2017; 
Before-after 
comparative 
effectiveness 
cohort
Screening 
intervention, 
EMR prompt
Urban inner-city 
hospital with 
high number of 
low-income and 
minority 
patients, 
Highland 
Hospital, 
Oakland, 
California
2,968/20,
975 
(14.2%)
153/2,968 
(5.2%)
6,972/19,
887 
(35.1%)
525/6,972 
(7.5%)
Abbreviations: anti-HCV = hepatitis C virus antibody; HCV = hepatitis C virus; RNA = ribonucleic acid; SVR = sustained virologic response; ED =
emergency department; IDU = injection drug use; LTC = linkage to care; EMR = electronic medical record.
* Partial overlap with Anderson 2016 (13) and Franco 2016 (16).
† 78.8% of tests among birth cohort patients.
§ 16 false-positives.
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¶ True positives less 9 without confirmatory viral load.SUPPLEMENTARY TABLE 8. Hepatitis C prevalence and linkagetocare, birth cohort
Author, 
publicatio
n year
Years of 
study;
design
Descriptio
n Setting
Anti-
HCV 
tested
Anti-
HCV 
positivity
RNA 
positivity
Follow-up
appt. 
arranged
Attended 
follow-up 
appt. Treated
Achieved 
SVR
Armstrong 
(30), 2019
2015–2017; 
Retrospective
Examining 
effects of e-
clinical 
decision 
support tool
Urban health 
system Cook 
County Health, 
Illinois
15,630 844/15,630 
(5.4%)
347/605 
(57.4%)
198/347 
(57.1%)
68
Bakhai (31), 
2019*
2015–2017; 
Prospective
Screening 
initiative
Academic 
internal medicine
residency 
program, 
Buffalo, New 
York
391/1,29
1 
(30.3%)
170/391 
(43.5%)
162/170 
(95.3%)
114/162 
(70.4%)
Bourgi (32), 
2016
2014–2015; 
Retrospective 
cohort
EMR prompt 21 internal 
medicine clinics 
at large 
integrated health 
system, Henry 
Ford Health 
System, 
Southeast 
Michigan
8,657/40,
561 
(21.3%)
109/8,657 
(1.3%)
65/69 
(94.2%)
51 30 
completed
Brady (33), 
2018
2012–2015; 
Retrospective
Birth-Cohort 
Evaluation to 
Advance 
Screening 
and Testing 
of Hepatitis C
(BEST-C)
3 medical centers 130 75/118 
(63.6%)
73/75 
(97.3%)
21/73 
(28.8%)
14/21 
(66.7%)
Castrejon 
(34), 2017
Pre: 2014–
2015; Post: 
2015–2016; 
Interrupted time
series
EMR prompt,
care 
coordinator
Outpatient clinic 
within large, 
complex health 
system with 
broad catchment 
area in Southern 
California, 
University of 
California at Los
Angeles
190/5,676 
(3.3%)
40/73 
(54.8%)
35/40 
(87.5%)
240/13,930 
(1.7%)
49/124 
(39.5%)
46/49 
(93.9%)
Cole (35), 2013–2015; Assessment 22 primary care 3,516/32, 565/3,516 
16
2019 Retrospective of screening 
and 
prevalence
practices in 
Washington, 
Wyoming, 
Alaska, 
Montana, Idaho
139 
(10.9%)
(16.1%)
Cornett (36), 
2018
2016; 
Retrospective 
cohort
Opt-out 
screening, 
EMR prompt
Large emergency
department in 
tertiary care 
hospital serving 
socio-
economically 
diverse patient 
population, 
Rutgers, New 
Jersey
192/2,928 
(6.6%)
71/167 
(42.5%)
De la Torre 
(37), 2019
2016–2017; 
Retrospective
Screening 
initiative
Birth cohort and 
immigrants from 
countries with 
endemic HCV
10,726 855/10,726 
(8.0%)
646†/855 
(75.6%)
436 109§
Deerin (38), 
2018
2014; Pilot 
study
Surveillance Washington, 
D.C.
196 58/196 
(29.6%)
29/31 
(93.5%)
Federman 
(39), 2017
2013–2014; 
Cluster 
randomized 
controlled trial
EMR prompt 
and provider 
training
Academically-
affiliated 
primary care 
practices of 
Mount Sinai 
Healthcare in 
NYC and Long 
Island
2,995/14,
825 
(20.2%)
27/8,713 
(0.3%)
198/10,7
95 
(1.8%)
6/5,438 
(0.1%)
Fitch (40), 
2017
2014–2015; 
Data reported in
a letter to the 
editor
Screening 
reminder, 
EMR prompt
2 hospital-based 
primary care 
clinics at Wake 
Forest, North 
Carolina
854/4,35
5 
(19.6%)
59/480 
(12.3%)
1,220/4,9
94 
(24.4%)
1,700/5,5
78 
(30.5%)
218/1,220 
(17.9%)
Geboy (41), 
2019
2015–2016; 
Prospective
Clinical 
decision 
support 
prompt
Largest 
distributed care 
delivery network
in Maryland and 
9,304/80,
556 
(11.6%)
353/9,304 
(3.8%)
186/311 
(59.8%)
161/186 
(86.6%)
123/161 
(76.4%)
48/123 
(39.0%)
42/48 
(87.5%)
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Washington, 
D.C. region, 
MedStar Health
Goel (42), 
2017
2013–2015; 
Prospective, 
stepwise, 
interventional
HCV 
screening and
LTC 
initiative, 
EMR prompt,
provider 
training, data 
feedback, 
patient 
navigator
Two primary 
care practices 
affiliated with 
tertiary care 
hospital and liver
transplant center,
Mount Sinai 
Hospital, New 
York City
4,419/14,
642¶ 
(30.2%)
147/4,419 
(3.3%)
84/134 
(62.7%)
60/84 
(71.4%)
32/60 
(53.3%) 
initiated; 6 
completed
6/6 
(100.0%)
Golden (43), 
2017
2011–2015; 
Time series
EMR orders 3 primary care 
clinic serving 
low-income 
patients, 
Harborview 
Medical Center, 
Seattle, 
Washington
681/3,77
3 
(18.0%)
135/681 
(19.8%)
97/134 
(72.4%)
1,185/3,3
36 
(35.5%)
123/1,185 
(10.4%)
85/122 
(69.7%)
Hossain (44), 
2017**
2013–2015; 
Cross-sectional
Screening 
intervention
Outpatient 
gastroenterology 
and hepatology 
clinics, Brooklyn
Methodist 
Hospital, 
Brooklyn, New 
York
245/423 
(57.9%)
5/245 
(2.0%)
2/5 (40.0%)
Isho (45), 
2017
Pilot Screening 
and education
intervention
Community 
pharmacy with 
large urban 
health center, 
University of 
Illinois Hospital 
and Health 
Sciences System,
Chicago, Illinois
16/50 
(32.0%)
0/16 (0.0%)
Jain (46), 
2019††
2013–2017; 
Retrospective
Screening 
intervention
Safety net 
hospital, 
Parkland Health 
System, Dallas, 
9,354/62,
331 
(15.0%)
1,542/9,354 
(16.5%)
723/968 
(74.7%)
373/723 
(51.6%)§§
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Texas
Jonas (47), 
2016
2014–2015; 
Prospective
Screening 
and LTC 
initiative, 
EMR prompt,
care 
coordinator
Kaiser 
Permanente Mid-
Atlantic States 
(Maryland, 
Virginia, and 
DC)
365/11,200 
(3.3%)
277/365 
(75.9%)
Kim (48), 
2019
2014–2017; 
Retrospective
Examining 
cascade of 
care
Primary care 
clinics in San 
Francisco, 
California
33,213/3
4,810 
(95.4%)
4,587/33,21
3 (13.8%)
2,827/4,587 
(61.6%)¶¶
634/900 
(90.6%)
Konerman 
(49), 2017
Interrupted time
series
EMR prompt 13 primary care 
clinic locations 
within 30mile 
radius of Ann 
Arbor, Michigan
1,705/22,
488 
(7.6%)
36/1,705 
(2.1%)
23/31 
(74.2%)
19,847/2
7,789 
(71.4%)
178/19,847 
(0.9%)
56***/168 
(33.3%)
53/53 
(100.0%)
46/53 
(86.8%)
20/36 
initiated; 9 
completed
9
Laufer (50), 
2015
2011–2014; 
Retrospective 
case control
Quality 
improvement 
initiative, 
screening 
intervention
Military retirees 
presenting to 
internal medicine
clinic
5/221 
(2.3%)
4/5 (80.0%)
10/478 
(2.1%)
2/10 
(20.0%)
MacLean 
(51), 2018
2013–2016; 
Retrospective 
cohort
EMR prompt Primary care at 
academic 
medical center 
serving urban 
and rural 
population, 
University of 
Vermont 
Medical Center
9,302/25,
071 
(37.1%)
319/9,302 
(3.4%)
164/182 
(90.1%)
Madhani 
(52), 2017
2013–2016; 
Retrospective 
chart review
Screening 
intervention, 
conferences, 
reminders, 
posters
Primary care at 
academic 
continuity 
practice, 
Waterbury, 
Connecticut
13/200 
(6.5%)
0/13 (0.0%)
13/100 
(13.0%)
1/13 (7.7%)
Rowan (53), 
2019†††
2013–2014; 
Prospective
Screening 
initiative
2 urban 
community 
health centers 
near Denver, 
Colorado
3,126/3,9
40 
(79.3%)
329/3,126 
(10.5%)
289/421 
(68.6%)
137/289 
(47.4%)
80 65/80 
(81.2%)§§§
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Sears (54), 
2013
2010–2011; 
Feasibility pilot 
study
Patients with and
without risk 
factors scheduled
for an outpatient 
colonoscopy 
with Scott & 
White 
Healthcare in 
Temple, Texas
346/483 
(71.6%)
4/346 
(1.2%)
1/4 (25.0%) 1/1 
(100.0%)
Shahnazarian 
(55), 2015¶¶¶
2013–2015; 
Retrospective
EMR prompt New York 
Methodist 
Hospital primary
care and 
outpatient clinics
and inpatients, 
Brooklyn, New 
York
9,551/15,
965 
(59.8%)
335/9,551 
(3.5%)
Sidlow (56), 
2015
2014; 
Retrospective 
cohort
EMR prompt Primary care 
clinics of North 
Bronx 
Healthcare 
Network
851/7,76
4 
(11.0%)
21/851 
(2.5%)
3,012/6,5
77 
(45.8%)
26/3,012 
(0.9%)
Turner (57), 
2015
2012–2014; 
Prospective 
cohort
Promotora 
(community 
health 
worker) assist
with LTC
Inpatients at 
hospital serving 
high indigent and
Hispanic 
population, 
University 
Hospital in San 
Antonio
4,582/5,0
87 
(90.1%)
316/4,582 
(6.9%)
175/287 
(61.0%)
65/175 
(37.1%)
14/65 
(21.5%)
Yartel (58), 
2018
2012–2014; 
Three 
randomized 
controlled trials
Trial 1) 
Repeated 
mailings, 
outreach
Primary care 
clinics part of 
academic 
medical centers: 
Trial 1) Henry 
Ford, Michigan 
[9 clinics]
805/2,99
3 
(26.9%)
8/805 
(1.0%)
84/5,999 
(1.4%)
2/84 (2.4%)
Trial 2) EMR
prompt
Trial 2) Mt. 
Sinai, New York 
[10 clinics]
757/8,92
8 
(30.9%)
27/2,757 
(1.0%)
197/5,54 6/197 
20
7 (3.6%) (3.0%)
Trial 3) 
Direct patient
solicitation
Trial 3) 
University of 
Alabama, 
Birmingham, 
Alabama [4 
clinics])
2,763/4,3
07 
(63.5%)
34/2,736 
(1.2%)
92/4,566 
(2.0%)
5/92 (5.4%)
Yeboah-
Korang (59), 
2018
2010–2015; 
Retrospective
Medical 
record review
North Shore 
University 
Health System, 
Illinois
11,976/1
06,753 
(11.2%)
670/11,976 
(5.6%)
Younossi 
(60), 2016
2014–2015; 
Prospective
Pilot 
screening 
program
Five 
gastroenterology 
centers close to 
large 
metropolitan 
areas on East 
Coast
10/2,000 
(0.5%)
4/9 (44.4%) 4/4 
(100.0%)
Abbreviations: anti-HCV = hepatitis C virus antibody; HCV = hepatitis C virus; RNA = ribonucleic acid; SVR = sustained virologic response; EMR
= electronic medical record; LTC = linkage to care.
* Numbers did not reconcile.
† Not RNA-negative or expired.
§ Of those linked.
¶ Of 14,642, 5,541 previously screened and therefore 9,101 eligible.
** Extended birth cohort members, age 40-75 years.
†† Pre- and post- combined.
§§ Not defined.
¶¶ Among anti-HCV positives; 1,484 had RNA testing without anti-HCV testing.
*** 3 not confirmed on subsequent testing.
††† Includes 92 persons not tested but self-reporting anti-HCV positivity.
§§§ 15 without SVR includes 13 followed for less than 12 weeks and 2 who did not return for testing.
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¶¶¶ From supplement.SUPPLEMENTARY TABLE 9. Hepatitis C prevalence and linkagetocare, others/multiple
Author, 
publicatio
n year
Years of 
study;
design
Descriptio
n Setting
Anti-
HCV 
tested
Anti-
HCV 
positivity
RNA 
positivity
Follow-up
appt. 
arranged
Attended 
follow-up 
appt. Treated
Achieved 
SVR
Arnold (61), 
2018
Prospective Mixed-
methods
African 
American adults 
with serious 
mental illness, 
Mid-Atlantic
/170 31/170 
(18.2%)
24 18/24 
(75.0%)
Burrell (62), 
2018
2017–2018; 
Retrospective
EMR 
protocol
Persons at risk 
for HCV in 
urgent care 
settings, 
Appalachia
1,895/6,5
09 
(29.1%)
31/1,895 
(1.6%)
100.0%
Calner (63), 
2019
2016–2018; 
Observational 
cohort
Screening 
and treatment
initiative
Potentially atrisk
persons at safety 
net, urban, 
academic 
facility, Boston 
Medical Center
28,435/1,
150,000 
(2.5%)
3,047/28,43
5 (10.7%)
1,637/2,991 
(54.7%)
582 275 
initiated; 
199 
completed
147/199 
(73.9%)
Campbell 
(64), 2018
2015–2016; 
Prospective 
pilot study
Screening 
offered 
during 
outpatient 
endoscopy
Patients with risk
factors 
presenting for 
outpatient 
endoscopy at an 
urban safety net 
hospital, 
Highland 
Hospital, 
Oakland 
California
318/596 
(53.4%)
14/318 
(4.4%)
6/11 
(54.5%)
6/6 (100%)
Coyle (65), 
2019
2012–2016; 
Retrospective
Testing and 
LTC 
initiative
Others at 
potential risk at 5
federally-
qualified health 
centers, 
Philadelphia, 
Pennsylvania
14,790 /
25,853 
(57.2%)
1,323/14,79
0 (8.9%)
885/1,272 
(69.6%)
732/885 
(82.7%)
614/732 
(83.9%)
133/614 
(21.7%) 
initiated;106
/614 
(17.3%) 
completed
71/106 
(67.0%)*
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De la Torre 
(66), 2017
2016; 
Descriptive
Audio 
Computer-
assisted 
screening 
interview 
(Audio-
CASI) Risk 
assessment 
kiosk, patient 
navigator, 
and EMR 
prompt
Academic 
charity care 
internal medicine
clinic and urban 
federally-
qualified health 
center (FQHC)
254/1,93
2 
(13.2%)
24/254 
(9.4%)
16/24 
(66.7%)
671/8,481 
(7.9%)
221/269 
(82.2%)
Duinnick 
(67), 2019
2012–2016; 
Retrospective
EMR review Patients 
diagnosed with 
hepatocellular 
carcinoma at 
Grady Memorial 
Hospital, 
Atlanta, Georgia
102/134 
(76.1%)
Falade-
Nwulia (68), 
2016
2014; 
Prospective
Promotional 
fliers
Six senior 
centers, 
Baltimore, 
Maryland
14/149 
(9.4%)
12/14 
(85.7%)
3/12 
(25.0%)
Fill (69), 
2018
2016; 
Prospective and
nested case-
control
Routine opt-
out and opt-in
HCV testing
Health 
department 
screening 
program in STI, 
family planning 
clinics, and 
addiction 
treatment 
facilities, Eastern
Tennessee
397/4,753 
(8.4%)
294/397 
(74.1%)
Ford (70), 
2018
2012–2013; 
Prospective
Check HepC 
Program, 
screening and
LTC 
initiative, 
targeted 
outreach and 
patient 
navigators
12 federally-
qualified health 
centers, SEPs, 
New York City
880/4,751 
(18.5%)
512/678 
(75.5%)
435/512 
(85.0%)
14 initiated; 
6 completed
6/6 
(100.0%)
23
Gade (71), 
2018
Retrospective 
observational
Adults with 
congenital heart 
disease who 
underwent 
cardiac surgery 
before 1992, 
Greenville 
Hospital System,
Greenville, 
South Carolina
116/188 
(61.7%)
12/116 
(10.3%)
11/12 
(91.7%)
11/11 
(100.0%)
11/11 
(100.0%)
5/11 
(45.5%)
5/5 
(100.0%)
Irvin (72), 
2016
2014–2015; 
Cross-sectional
Community-
academic 
partnership to
promote 
testing
Testing efforts 
were pursued 
through 
advertising at 
community 
block parties, 
intersections 
frequented by 
PWID, shelters, 
etc. at 35 
locations in 
Baltimore City
49/325 
(15.1%)
Lier (73), 
2019†
2016–2018; 
Retrospective
Determining 
HCV 
prevalence
Birth cohort and 
IDU at suburban 
medical center
1,017/27,11
9 (3.8%)
437/929 
(47.0%)
153 53
McClure 
(74), 2019§
2011–2015; 
Retrospective
Examining 
the 
relationship 
between 
illicit drug 
use and HCV
Others at risk 
(Note: lab results
from people with
both urine screen
and HCV results)
4,628/18,41
0 (25.1%)
Mera (75), 
2016
2012–2015 EMR prompt,
provider 
training, 
ECHO 
clinics, 
registry, 
outreach
Cherokee Nation
Health Services
16,772/9
2,012 
(18.2%)
715/16,772 
(4.3%)
388/488 
(79.5%)
223/388 
(57.5%) 
initiated;201
/388 
(51.8%) 
completed
180/201 
(89.6%)
Morano (76), 
2014
2012–2013; Mobile 
medical clinic
Mobile medical 
clinic clients in 
poor city, New 
Haven, 
438/1,34
5 
(32.6%)
27/438 
(6.2%)
27/27 
(100.0%)
9/17 
(52.9%)
24
Connecticut
Morse (77), 
2017
2012–2014; 
Prospective
Collaborative
community 
post-
incarceration 
program
Women recently 
released from 
incarceration
60/87 
(69.0%)
12/60 
(20.0%)
Patil (78), 
2016
2014–2015; 
Numbers 
reported via 
journal 
commentary
Screening 
initiative
94 local health 
units targeting 
IDUs and birth 
cohort patients in
Arkansas
325/3,544 
(9.2%)
Ramirez (79),
2016¶
2012–2014; 
Retrospective
HepTLC 
initiative
At-risk 
population, 206 
testing sites in 17
states
7,580/57,57
0 (13.2%)
3,449/4,765 
(72.4%)
2,624/3,449 
(76.1%)
1,509/2,624 
(57.5%)
Robinson 
(80), 2018**
2014–2015; 
Retrospective
Evaluation 
for patients 
with cirrhosis
Patients with 
cirrhosis at an 
urban safety net 
hospital, 
California
47/157 
(29.9%)
Takeuchi 
(81), 2015
2010–2013; 
Retrospective
Screening 
those with 
risk factors
Hawaii's health 
department; 
community 
health sites
508/8,588 
(5.9%)
Trooskin 
(82), 2015
2012–2014; 
Prospective
Screening 
and LTC 
initiative, 
patient 
navigators
Mobile medical 
unit, 
Philadelphia, 
Pennsylvania
52††/1,301 
(4.0%)
36/42 
(85.7%)
23/36 
(63.9%)
21/23 
(91.3%)
12
Zaller (83), 
2016
2010–2014; 
Pilot study
Screening 
and LTC 
initiative
Persons on 
probation or 
parole, 
Providence and 
Pawtucket, 
Rhode Island
12/130 
(9.2%)
2/4 (50.0%) 2/2 
(100.0%)
0/2 (0.0%)
Abbreviations: anti-HCV = hepatitis C virus antibody; HCV = hepatitis C virus; RNA = ribonucleic acid; SVR = sustained virologic response; EMR
= electronic medical record; STI = sexually transmitted infection; SEP = syringe exchange program; IDU = injection drug use; ECHO = Extension 
for Community Healthcare Outcomes; HepTLC = Hepatitis Testing and Linkage to Care initiative.
* 77 assessed for SVR.
† LTC definition not provided.
§ Results include persons with urine screen.
25
¶ An additional 7,146 RNA tests conducted without prior anti-HCV testing.
** 47 with chronic HCV infection.
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†† 4 persons previously engaged in care.SUPPLEMENTARY TABLE 10. Hepatitis C prevalence and linkagetocare, persons who use drugs
Author, 
publicatio
n year
Years of 
study;
design
Descriptio
n Setting
Anti-
HCV 
tested
Anti-
HCV 
positivity
RNA 
positivity
Follow-up
appt. 
arranged
Attended 
follow-up 
appt. Treated
Achieved 
SVR
Aronson (84),
2017
2016; 
Feasibility pilot 
study
Tablet 
computer 
based 
educational 
intervention
SEP clients, 
Bronx, New 
York
10/10 
(100.0%)
2/10 
(20.0%)
Burton (85), 
2019
2014–2018; 
Retrospective
Screening 
intervention
G.V. (Sonny) 
Montgomery 
Veteran’s 
Administration 
residential 
substance use 
disorder 
treatment center, 
Southeastern 
United States
582/597 
(97.5%)
74/582 
(12.7%)
74/74 
(100.0%)
74/74 
(100.0%)
51/67 
(76.1%) 
initiated
41/51 
(80.4%)
Des Jarlais 
(86), 2018
2011–2015; 
Cross-sectional
Geographic 
hotspot 
identification
NYC drug 
detoxification 
and methadone 
maintenance 
programs, Mount
Sinai, Beth Israel
493/910 
(54.2%)
Des Jarlais 
(87), 2019
2016–2018; 
Prospective
Examining 
outcomes 
among PWID
in drug 
treatment
Drug treatment 
programs at 
Mount Sinai 
Beth Israel, New 
York City
134 79/134 
(59.0%)
Jordan (88), 
2015
2010–2013; 
Cross-sectional
Survey Detoxification 
program or 
MMT program, 
New York City
536/826 
(64.9%)
Neaigus (89),
2017
2012; Cross-
sectional
National HIV 
Behavioral 
Surveillance 
System, New 
York City
483/525 
(92.0%)
324/483 
(67.1%)
Quinn (90), 
2019
2014–2016 Risk 
knowledge 
scale
Young opioid 
users in New 
York City
105/539 
(19.5%)
27
Stockman 
(91), 2014
2012–2013; 
Pilot study
Rapid point-
of-care 
screening 
initiative
4 community-
based 
organizations for
PWUD in 
Wisconsin
246/1,255 
(19.6%)
128/183 
(69.9%)
Talal (92), 
2017
2012–2013; 
Prospective
Assess HCV 
core antigen
Opioid agonist 
therapy program,
West Harlem, 
New York
65/109 
(59.6%)
48*/65 
(73.8%)
Tsui (93), 
2019
2015; Cross-
sectional
National HIV 
Behavior 
Surveillance 
System, Seattle 
metropolitan 
area
513/535 
(95.9%)
338/513 
(65.9%)
Zibbell (94), 
2014
2012; Cross-
sectional
Screening 
initiative
PWID recruited 
from a 
community-
based AIDS 
organization, 
residing in 
Cortland County 
(rural), New 
York
100/123 
(81.3%)
34/100 
(34%)
Abbreviations: anti-HCV = hepatitis C virus antibody; HCV = hepatitis C virus; RNA = ribonucleic acid; SVR = sustained virologic response; SEP 
= syringe exchange program; PWID = persons who inject drugs; MMT = methadone maintenance treatment; PWUD = persons who use drugs.
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* 1 with negative anti-HCV.SUPPLEMENTARY TABLE 11. Hepatitis C prevalence and linkagetocare, persons with HIV or sexual risk
Author, 
publicatio
n year
Years of 
study;
design
Descriptio
n Setting
Anti-
HCV 
tested
Anti-
HCV 
positivity
RNA 
positivity
Follow-up
appt. 
arranged
Attended 
follow-up 
appt. Treated
Achieved 
SVR
Falade-
Nwulia (95), 
2016
2013–2014; 
Cross-sectional
Care 
coordinator
2 STI clinics, 
Baltimore City 
Health 
Department
2,681/6,2
90 
(42.6%)
189/2,681 
(7.0%)
155/185 
(83.8%)
132/155 
(85.2%)
81/132 
(61.4%)
Feldman 
(96), 2017
2014–2015; 
Cross-sectional
Free 
screening
Community 
health center, 
STI clinic 
Miami, Florida
21*/357 
(5.9%)
Jewett (97), 
2013
2012; Cross-
sectional
Staff training STI and HIV 
testing facility, 
Denver Metro 
Health Clinic
876/926 
(94.6%)
33/876 
(3.8%)
21/32 
(65.6%)
Kalichman 
(98), 2015
2012–2014; 
Cross-sectional
Screened as 
part of study
Receiving ART 
in Atlanta, 
Georgia
131/678 
(19.3%)
Moss (99), 
2014
2011–2012; 
Retrospective
No-cost, opt-
in testing
AIDS 
community-
based 
organization 
catering to 
minority MSM, 
Miami, Florida
326/2,98
8 
(10.9%)
4/326 
(1.2%)
Radwan 
(100), 2019†
2014–2015; 
Retrospective 
cohort study
HIV infected 
patients 
screened for 
HCV
12 sites of HIV 
research network
(3 regions of 
U.S.)
22,632/2
9,071 
(77.9%)
7,447/22,63
2 (32.9%)
4,305/7,047 
(61.1%)
387 277/291§ 
(95.2%)
Raymond 
(101), 2012
2011; Cross-
sectional
National HIV 
Behavioral 
Surveillance 
System, San 
Francisco, 
California
21/466 
(4.5%)
Tieu (102), 
2018
2010–2013; 
Cross-sectional
MSM residing in
New York City
29/1,028 
(2.8%)
12/29 
(41.4%)
Abbreviations: anti-HCV = hepatitis C virus antibody; HCV = hepatitis C virus; RNA = ribonucleic acid; SVR = sustained virologic response; STI 
= sexuallytransmitted infection; ART = antiretroviral therapy; MSM = men who have sex with men.
* Confirmed by RNA testing.
29
† 2,179 at sites with prescription data.
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§ Tested for SVR.SUPPLEMENTARY TABLE 12. Hepatitis C prevalence and linkagetocare, immigrants
Author, 
publicatio
n year
Years of 
study;
design
Descriptio
n Setting
Anti-
HCV 
tested
Anti-
HCV 
positivity
RNA 
positivity
Follow-up
appt. 
arranged
Attended 
follow-up 
appt. Treated
Achieved 
SVR
Ma (103), 
2015
2010–2011; 
Prospective
HCV 
educational 
program
7 Vietnamese 
community 
organizations, 
Pennsylvania 
and New Jersey
255/309 
(82.5%)
19/255 
(7.5%)
Saab (104), 
2018
Cross-sectional Screening 
opportunity
7 houses of 
worship with 
large numbers of
Egyptian 
immigrants in 
Southern 
California
11/326 
(3.4%)
9/11 
(81.8%)
Strong (105), 
2015
2011; Cross-
sectional
Free testing 
was offered
Vietnamese 
health fair in the 
Baltimore-
Washington 
metropolitan 
area
29/617 
(4.7%)
31
Abbreviations: anti-HCV = hepatitis C virus antibody; HCV = hepatitis C virus; RNA = ribonucleic acid; SVR = sustained virologic 
response.SUPPLEMENTARY TABLE 13. Hepatitis C prevalence among pregnant women
Author, 
publication year
Years of 
study;
design Description Setting Anti-HCV tested
AntiHCV 
positivity RNA positivity
Bell (106), 2019 2013–2018; 
Retrospective 
cohort
Analysis of infants with 
neonatal abstinence 
syndrome
Tertiary care center in 
Southern Maine
536/769 (69.7%) 257/536 (48.0%)
Berkley (107), 2008 2000–2006; 
Retrospective
Comparison of HCV-
infected and uninfected 
pregnancies
Hospital drug dependence
and treatment program, 
Milagro Clinic, 
University of New 
Mexico
300/351 (85.5%) 159/300 (53.0%) 16/26 (61.5%)
Boudova (108), 2018 2016; 
Retrospective
Secondary data analysis 
using EMR
University of Maryland 
Medical Center, 
Baltimore
100/1,426 (7.0%) 10/100 (10.0%)
Brogly (109), 2018 2015–2016; 
Prospective 
cohort
Project RESPECT 
(Recovery-Empowerment-
Social Services-Prenatal 
Care-Education-
Community-Treatment)
Obstetrics addiction 
recovery clinic at urban 
safety net hospital, 
Boston, Massachusetts
80/113 (70.8%)
Chappell (110), 2018 2006–2014; 
Retrospective 
cohort
Infant records linked to 
HCVinfected mothers, 
billing codes
Large tertiary care referral
hospital, Magee Women’s
Hospital, University of 
Pittsburgh Medical Center
1,043/87,924 (1.2%)
Ellington (111), 2015 2002–2010; 
Data analysis
Hospital discharge data Nationwide Inpatient 
Sample (HCUP)
70,367/41,479,358* 
(0.2%)
Epstein (112), 2018 2006–2015; 
Cohort
Project RESPECT 
(Recovery-Empowerment-
Social Services-Prenatal 
Care-Education-
Community-Treatment)
Women with diagnosis of 
opioid use disorder, 
Boston Medical Center, 
Boston, Massachusetts
744/879 (84.6%) 510/744 (68.6%) 261/369 (70.7%)
Gowda (113), 2018† 2012–2015; 
Data analysis
Surveillance and birth 
certificate data match
Ohio 2,151/140,127 (1.5%)
Jessop (114), 2005 2000–2001; 
Chart 
abstraction
Chart abstraction Probability sample of 
Philadelphia births
27/550 (4.9%) 3/27 (11.1%)
Ko (115), 2019 2000–2015; 
Data analysis
Delivery hospitalizations Nationwide Inpatient 
Sample (HCUP)
11,615/2,860,110 
(0.4%)
Koneru (116), 2016 2011–2014; 
Data analysis
Birth certificate data Kentucky and United 
States
KY: 1.6%
US: 0.3%
32
Krans (117), 2016 2009–2012; 
Retrospective 
cohort
EMR data abstraction Women on opioid 
maintenance therapy, 
large tertiary care referral 
hospital in metropolitan 
area, Magee Women’s 
Hospital, University of 
Pittsburgh Medical Center
611§/791 (77.2%) 369/611 (60.4%)
Kuncio (118), 2016 2011–2013; 
Data analysis
Surveillance and birth 
certificate data match
Philadelphia residents 568/55,623 (1.0%)
Lazenby (119), 2019 2013–2016; 
Retrospective
Chart review Academic obstetric clinic,
Medical University of 
South Carolina
123/16,918 (0.7%) 38/123 (30.9%)
Ly (120), 2017 2011–2014; 
Data analysis
Quest Diagnostics Health 
Trends national database
Nationwide laboratory 
data
4,232/581,255 (0.7%)
McDowell (121), 2019 2015–2018; 
Retrospective 
cohort
Study of women with 
antenatal exposure to 
buprenorphine
Maternal opioid use 
disorder recovery 
program, Indiana 
University School of 
Medicine
103¶/266 (38.7%)
Nolen (122), 2019 2013–2016; 
Retrospective 
analysis
EMR data abstraction Obstetrics clinic and 
Alaska Native Tribal 
Health System referral 
hospital, Alaska
1,356/2,856 (47.5%) 62/1,356 (4.6%) 38/62 (61.3%)
Nolen (123), 2019 2003–2015; 
Data analysis
Birth certificate and Indian 
Health Service data
American Indian and 
Alaska native women
AI/AN: 398/33,434 
(1.19%)
NonAI/AN: 
11,660/3,266,257 
(0.36%)
IHS: 216/23,374 
(0.92%)
Page (124), 2017 Secondary 
analysis of 
laboratory 
results
Two prospective cohort 
studies
Prenatal clinic for women 
with substance use, 
Milagro Clinic, 
University of New 
Mexico
178/190 (93.7%) 95/178 (53.3%) 71/92 (77.2%)
Patrick (125), 2017 2009–2014; 
Data analysis
Birth certificate data Tennessee and United 
States
TN: 10.1 per 1,000 
live births
US: 3.4 per 1,000 
live births
Salemi (126), 2017 1998–2011; 
Retrospective, 
cross-sectional 
Delivery hospitalization Nationwide Inpatient 
Sample (HCUP)
62,629/52,807,699 
(0.1%)
33
analysis
Salihu (127), 2012 1998–2007; 
Population-
based 
retrospective 
cohort
Surveillance-hospital 
discharge data linked to 
birth records
All Florida singleton live 
births
1,023/1,700,734 
(0.1%)
Schillie (128), 2018 2011–2016; 
Data analysis
Birth certificate and 
commercial laboratory data
United States 13.4% 14,417/3,823,723 
(0.38%)
Snodgrass (129), 2018 2015; 
Surveillance 
and birth 
certificate data 
match
Surveillance and birth 
certificate data match
Oregon 294/44,712 (0.7%)
Waruingi (130), 2015 2012; 
Prospective 
observational 
study
Comparison of risk-based 
vs. universal screening
Metro Health Medical 
Center, Case Western 
Reserve University; 
Cleveland, Ohio
220/419 (47.7%) 7/220 (3.2%)
Watts (131), 2017 2011–2015; 
Data analysis
Surveillance data linked to 
Medicaid data
Wisconsin Medicaid 
recipients
608/146,267 (0.4%)
Abbreviations: anti-HCV = hepatitis C virus antibody; HCV = hepatitis C virus; RNA = ribonucleic acid; EMR = electronic medical records; HCUP
= healthcare cost and utilization project; AI/AN = American Indian/Alaska Native; HIS = Indian Health Service.
* Number of hospital admissions
† RNA positivity reported in study but not included as surveillance data may under-represent RNA negative results.
§ HCV screening defined as documentation of anti-HCV test or prior discussion regarding known HCV diagnosis.
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¶ All with HCV RNA positivity.References
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